{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:53:51Z","timestamp":1792180431851,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002163","name":"Johnson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention Research Institute of Texas (CPRIT)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clgc.2018.09.005","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T22:51:36Z","timestamp":1536706296000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl Lyn","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-0635","authenticated-orcid":false,"given":"Chung-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Carden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannicola","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Marston","family":"Linehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5672-0961","authenticated-orcid":false,"given":"Priya","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Grodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Dome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0746-8306","authenticated-orcid":false,"given":"Conrad V.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I.","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"Apolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najat C.","family":"Daw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4441-497X","authenticated-orcid":false,"given":"H. Courtney","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marva","family":"Moxey-Mims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darmood","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Bottaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Staehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4984-0225","authenticated-orcid":false,"given":"W. Kimryn","family":"Rathmell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2018.09.005_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-199501000-00001","article-title":"Renal medullary carcinoma. The seventh sickle cell nephropathy","volume":"19","author":"Davis","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2018.09.005_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JOP.2017.020909","article-title":"Renal medullary carcinoma: establishing standards in practice","volume":"13","author":"Beckermann","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clgc.2018.09.005_bib3","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bju.13705","article-title":"Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study","volume":"120","author":"Shah","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2018.09.005_bib4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2012.06.043","article-title":"A\u00a0phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma","volume":"62","author":"Tannir","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2018.09.005_bib5","series-title":"Seldin and Giebisch\u2019s The Kidney","first-page":"595","article-title":"Chapter 20 - Structural organization of the mammalian kidney","author":"Kriz","year":"2013"},{"key":"10.1016\/j.clgc.2018.09.005_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/PAS.0000000000001000","article-title":"Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma","volume":"42","author":"Ohe","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2018.09.005_bib7","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/PAS.0b013e318299f2d1","article-title":"The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia","volume":"37","author":"Srigley","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2018.09.005_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cancergen.2014.07.004","article-title":"Pathology and diagnosis of SMARCB1-deficient tumors","volume":"207","author":"Margol","year":"2014","journal-title":"Cancer Genet"},{"key":"10.1016\/j.clgc.2018.09.005_bib9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/modpathol.2008.44","article-title":"Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior","volume":"21","author":"Cheng","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clgc.2018.09.005_bib10","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.5858\/2003-127-e135-RMCARO","article-title":"Renal medullary carcinoma: a report of 2 cases and review of the literature","volume":"127","author":"Dimashkieh","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clgc.2018.09.005_bib11","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.eururo.2015.09.027","article-title":"Balanced translocations disrupting SMARCB1 are hallmark recurrent genetic alterations in renal medullary carcinomas","volume":"69","author":"Calderaro","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2018.09.005_bib12","doi-asserted-by":"crossref","first-page":"e987","DOI":"10.1016\/j.clgc.2017.04.012","article-title":"Genomic characterization of renal medullary carcinoma and treatment outcomes","volume":"15","author":"Carlo","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2018.09.005_bib13","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1078-0432.CCR-17-3296","article-title":"A\u00a0model linking sickle cell hemoglobinopathies and SMARCB1 loss in renal medullary carcinoma","volume":"24","author":"Msaouel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2018.09.005_bib14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.humpath.2017.07.006","article-title":"Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma","volume":"67","author":"Sirohi","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clgc.2018.09.005_bib15","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1177\/0193945916665089","article-title":"Knowledge and awareness of sickle cell trait among young African American adults","volume":"39","author":"Harrison","year":"2017","journal-title":"West J Nurs Res"},{"key":"10.1016\/j.clgc.2018.09.005_bib16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00001888-200308000-00003","article-title":"The importance of cognitive errors in diagnosis and strategies to minimize them","volume":"78","author":"Croskerry","year":"2003","journal-title":"Acad Med"},{"key":"10.1016\/j.clgc.2018.09.005_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cancergen.2014.04.004","article-title":"Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth","volume":"207","author":"Kim","year":"2014","journal-title":"Cancer Genet"},{"key":"10.1016\/j.clgc.2018.09.005_bib18","doi-asserted-by":"crossref","first-page":"a026930","DOI":"10.1101\/cshperspect.a026930","article-title":"The many roles of BAF (mSWI\/SNF) and PBAF complexes in cancer","volume":"6","author":"Hodges","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.clgc.2018.09.005_bib19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/modpathol.2010.213","article-title":"Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum","volume":"24","author":"Debelenko","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clgc.2018.09.005_bib20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/gcc.20839","article-title":"ALK rearrangement in sickle cell trait-associated renal medullary carcinoma","volume":"50","author":"Marino-Enriquez","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clgc.2018.09.005_bib21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/PAS.0000000000000179","article-title":"VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy?","volume":"38","author":"Smith","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2018.09.005_bib22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00247-017-3926-6","article-title":"Imaging of renal medullary carcinoma in children and young adults: a report from the Children\u2019s Oncology Group","volume":"47","author":"Sandberg","year":"2017","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.clgc.2018.09.005_bib23","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/pbc.25592","article-title":"Renal medullary carcinoma and sickle cell trait: a systematic review","volume":"62","author":"Alvarez","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clgc.2018.09.005_bib24","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.5489\/cuaj.2373","article-title":"Clinical outcome and prognostic factors in renal medullary carcinoma: a pooled analysis from 18 years of medical literature","volume":"9","author":"Iacovelli","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2018.09.005_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2018.09.005_bib26","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clgc.2018.09.005_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2018.09.005_bib28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1101\/gad.186411.111","article-title":"A\u00a0key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia","volume":"26","author":"Simon","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.clgc.2018.09.005_bib29","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1084\/jem.20131144","article-title":"Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders","volume":"210","author":"Muto","year":"2013","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clgc.2018.09.005_bib30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature21064","article-title":"Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer","volume":"542","author":"Genovese","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2018.09.005_bib31","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1200\/JCO.2005.05.0344","article-title":"Medullary renal cell carcinoma and response to therapy with bortezomib","volume":"24","author":"Ronnen","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.09.005_bib32","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.urology.2008.05.009","article-title":"High-dose-intensity MVAC for advanced renal medullary carcinoma: report of three cases and literature review","volume":"72","author":"Rathmell","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2018.09.005_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26402","article-title":"Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: two cases","volume":"64","author":"Carden","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clgc.2018.09.005_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1464-410X.2009.09139.x","article-title":"Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy","volume":"106","author":"Schaeffer","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2018.09.005_bib35","first-page":"735","article-title":"Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy","volume":"182","author":"Albadine","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2018.09.005_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-016-0206-1","article-title":"Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma","volume":"5","author":"Beckermann","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clgc.2018.09.005_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40425-017-0267-9","article-title":"Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition","volume":"5","author":"Sodji","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clgc.2018.09.005_bib38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ng.3746","article-title":"SMARCB1-mediated SWI\/SNF complex function is essential for enhancer regulation","volume":"49","author":"Wang","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2018.09.005_bib39","doi-asserted-by":"crossref","first-page":"8431","DOI":"10.1200\/JCO.2005.02.1568","article-title":"Pediatric phase I trials in oncology: an analysis of study conduct efficiency","volume":"23","author":"Lee","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.09.005_bib40","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1200\/JCO.2017.74.4144","article-title":"Modernizing clinical trial eligibility: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group","volume":"35","author":"Gore","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.09.005_bib41","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-09-0344","article-title":"Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy","volume":"15","author":"O\u2019Donnell","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2018.09.005_bib42","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood.V99.3.850","article-title":"Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait","volume":"99","author":"Kang","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2018.09.005_bib43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/14653240902849788","article-title":"Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?","volume":"11","author":"Fitzhugh","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clgc.2018.09.005_bib44","unstructured":"Developing Products for Rare Diseases & Conditions: Food & Drug Administration Office of Orphan Products Development, Available at: https:\/\/www.fda.gov\/ForIndustry\/DevelopingProductsforRareDiseasesConditions\/default.htm. Accessed: September 27, 2018."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318303847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318303847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:15Z","timestamp":1761564675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318303847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1558767318303847"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.09.005","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}